Regulatory T cells in systemic lupus erythematosus (SLE); Role of peptide tolerance

Autoimmunity Reviews

Volumn 11, Issue 9, 2012, Pages 611-614

  Sawla, Priya ^a   Hossain, Awlad ^a   Hahn, Bevra H ^a   Singh, Ram P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; CD4+Tregs; Immune tolerance; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3;

AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORTICOSTEROID THERAPY; GENE MUTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NONHUMAN; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ANIMALS; AUTOIMMUNITY; CD4 LYMPHOCYTE COUNT; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; PEPTIDES; T-LYMPHOCYTES, REGULATORY;

EID: 84861737557     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.09.008     Document Type: Review

References (71)

1. Hahn B.H. Lessons in lupus: the mighty mouse. Lupus 2001, 10:589-593.
2. La Cava A. T-regulatory cells in systemic lupus erythematosus. Lupus 2008, 17:421-425.
3. Singh R.P., Dinesh R., Elashoff D., de Vos S., Rooney R.J., Patel D., et al. Distinct gene signature revealed in white blood cells, CD4(+) and CD8(+) T cells in (NZBx NZW) F1 lupus mice after tolerization with anti-DNA Ig peptide. Genes Immun 2010, 11:294-309.
4. Bonelli M., Savitskaya A., Steiner C.W., Rath E., Smolen J.S., Scheinecker C. Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol 2009, 182:1689-1695.
5. Bonelli M., Savitskaya A., von Dalwigk K., Steiner C.W., Aletaha D., Smolen J.S., et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008, 20:861-868.
6. Franz B., Fritzsching B., Riehl A., Oberle N., Klemke C.D., Sykora J., et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007, 56:1910-1920.
7. Scheinecker C., Bonelli M., Smolen J.S. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun 2010, 35:269-275.
8. Lin S.C., Chen K.H., Lin C.H., Kuo C.C., Ling Q.D., Chan C.H. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest 2007, 37:987-996.
9. Suarez A., Lopez P., Gomez J., Gutierrez C. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006, 65:1512-1517.
10. Bonelli M., Smolen J.S., Scheinecker C. Treg and lupus. Ann Rheum Dis 2010, 69(Suppl 1):i65-i66.
11. Bach J.F. Regulatory T cells under scrutiny. Nat Rev Immunol 2003, 3:189-198.
12. Dinesh R.K., Skaggs B.J., La Cava A., Hahn B.H., Singh R.P. CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev 2010, 9:560-568.
13. Parietti V., Chifflot H., Muller S., Monneaux F. Regulatory T cells and systemic lupus erythematosus. Ann N Y Acad Sci 2007, 1108:64-75.
14. Gershon R.K., Kondo K. Infectious immunological tolerance. Immunology 1971, 21:903-914.
15. Nishizuka Y., Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969, 166:753-755.
16. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
17. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
18. Suri-Payer E., Amar A.Z., Thornton A.M., Shevach E.M. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998, 160:1212-1218.
19. Lee J.H., Wang L.C., Lin Y.T., Yang Y.H., Lin D.T., Chiang B.L. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 2006, 117:280-286.
20. Jordan M.S., Boesteanu A., Reed A.J., Petrone A.L., Holenbeck A.E., Lerman M.A., et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001, 2:301-306.
21. Alvarado-Sanchez B., Hernandez-Castro B., Portales-Perez D., Baranda L., Layseca-Espinosa E., Abud-Mendoza C., et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2006, 27:110-118.
22. Barath S., Aleksza M., Tarr T., Sipka S., Szegedi G., Kiss E. Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus. Lupus 2007, 16:489-496.
23. Gerli R., Nocentini G., Alunno A., Bocci E.B., Bianchini R., Bistoni O., et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 2009, 8:426-430.
24. Zheng S.G., Gray J.D., Ohtsuka K., Yamagiwa S., Horwitz D.A. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol 2002, 169:4183-4189.
25. Chen C.H., Seguin-Devaux C., Burke N.A., Oriss T.B., Watkins S.C., Clipstone N., et al. Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J Exp Med 2003, 197:1689-1699.
26. Schallenberg S., Tsai P.Y., Riewaldt J., Kretschmer K. Identification of an immediate Foxp3(-) precursor to Foxp3(+) regulatory T cells in peripheral lymphoid organs of nonmanipulated mice. J Exp Med 2010, 207:1393-1407.
27. Coombes J.L., Siddiqui K.R., Arancibia-Carcamo C.V., Hall J., Sun C.M., Belkaid Y., et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007, 204:1757-1764.
28. Probst-Kepper M., Geffers R., Kroger A., Viegas N., Erck C., Hecht H.J., et al. GARP: a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med 2009, 13:3343-3357.
29. Thornton A.M., Korty P.E., Tran D.Q., Wohlfert E.A., Murray P.E., Belkaid Y., et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010, 184:3433-3441.
30. Hahn B.H., Singh R.P., La Cava A., Ebling F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol 2005, 175:7728-7737.
31. Singh R.P., La Cava A., Hahn B.H. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol 2008, 180:2069-2080.
32. Singh R.P., La Cava A., Wong M., Ebling F., Hahn B.H. CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 2007, 178:7649-7657.
33. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005, 6:338-344.
34. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
35. Horwitz D.A. Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res Ther 2008, 10:227.
36. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 2006, 24:209-226.
37. Horwitz D.A. Identity of mysterious CD4+CD25-Foxp3+ cells in SLE. Arthritis Res Ther 2010, 12:101.
38. Pillai V., Ortega S.B., Wang C.K., Karandikar N.J. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007, 123:18-29.
39. Mantel P.Y., Ouaked N., Ruckert B., Karagiannidis C., Welz R., Blaser K., et al. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 2006, 176:3593-3602.
40. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37:129-138.
41. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354.
42. Roncarolo M.G., Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells?. Eur J Immunol 2008, 38:925-927.
43. Bonelli M., von Dalwigk K., Savitskaya A., Smolen J.S., Scheinecker C. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. Ann Rheum Dis 2008, 67:664-671.
44. Pryjma J., Flad H.D., Mytar B., Ennen J., Ernst M. Effect of dexamethasone on mechanisms responsible for regulation of polyclonal B-cell response. Int J Immunopharmacol 1989, 11:871-877.
45. Takenawa J., Kaneko Y., Okumura K., Yoshida O., Nakayama H., Fujita J. Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinomas and effects on expression of interleukin-6 or interleukin-6 receptor. J Urol 1995, 153:858-862.
46. Azab N.A., Bassyouni I.H., Emad Y., Abd El-Wahab G.A., Hamdy G., Mashahit M.A. CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clin Immunol 2008, 127:151-157.
47. Vallerskog T., Gunnarsson I., Widhe M., Risselada A., Klareskog L., van Vollenhoven R., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007, 122:62-74.
48. Yan B., Ye S., Chen G., Kuang M., Shen N., Chen S. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum 2008, 58:801-812.
49. Hahn B.H., Singh R.R., Wong W.K., Tsao B.P., Bulpitt K., Ebling F.M. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001, 44:432-441.
50. Ohnishi K., Ebling F.M., Mitchell B., Singh R.R., Hahn B.H., Tsao B.P. Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. Int Immunol 1994, 6:817-830.
51. Tsao B.P., Ebling F.M., Roman C., Panosian-Sahakian N., Calame K., Hahn B.H. Structural characteristics of the variable regions of immunoglobulin genes encoding a pathogenic autoantibody in murine lupus. J Clin Invest 1990, 85:530-540.
52. Singh R.R., Ebling F.M., Albuquerque D.A., Saxena V., Kumar V., Giannini E.H., et al. Induction of autoantibody production is limited in nonautoimmune mice. J Immunol 2002, 169:587-594.
53. La Cava A., Ebling F.M., Hahn B.H. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black×New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol 2004, 173:3542-3548.
54. Sharabi A., Zinger H., Zborowsky M., Sthoeger Z.M., Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc Natl Acad Sci U S A 2006, 103:8810-8815.
55. Eilat E., Dayan M., Zinger H., Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci U S A 2001, 98:1148-1153.
56. Sharabi A., Haviv A., Zinger H., Dayan M., Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin Immunol 2006, 119:146-155.
57. Sharabi A., Luger D., Ben-David H., Dayan M., Zinger H., Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol 2007, 179:4979-4987.
58. Sharabi A., Azulai H., Sthoeger Z.M., Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 2007, 121:248-257.
59. Rapoport M.J., Sharabi A., Aharoni D., Bloch O., Zinger H., Dayan M., et al. Amelioration of SLE-like manifestations in (NZB×NZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 2005, 117:262-270.
60. Mozes E., Sela U., Sharabi A. A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of action. Isr Med Assoc J 2008, 10:40-42.
61. Kang H.K., Michaels M.A., Berner B.R., Datta S.K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005, 174:3247-3255.
62. Riemekasten G., Langnickel D., Enghard P., Undeutsch R., Humrich J., Ebling F.M., et al. Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 2004, 173:5835-5842.
63. Alonso N., Soldevila B., Sanmarti A., Pujol-Borrell R., Martinez-Caceres E. Regulatory T cells in diabetes and gastritis. Autoimmun Rev 2009, 8:659-662.
64. Brand D.D., Myers L.K., Whittington K.B., Latham K.A., Stuart J.M., Kang A.H., et al. Detection of early changes in autoimmune T cell phenotype and function following intravenous administration of type II collagen in a TCR-transgenic model. J Immunol 2002, 168:490-498.
65. Lemere C.A., Maron R., Selkoe D.J., Weiner H.L. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 2001, 20:705-711.
66. Weiner H.L., Friedman A., Miller A., Khoury S.J., al-Sabbagh A., Santos L. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994, 12:809-837. et al.
67. Faria A.M., Weiner H.L. Oral tolerance and TGF-beta-producing cells. Inflamm Allergy Drug Targets 2006, 5:179-190.
68. Miyara M., Gorochov G., Ehrenstein M., Musset L., Sakaguchi S., Amoura Z. Human FoxP3(+) regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011.
69. Miyara M., Sakaguchi S. Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. Immunol Cell Biol 2011, 89:346-351.
70. Miyara M., Wing K., Sakaguchi S. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J Allergy Clin Immunol 2009, 123:749-755. quiz 56-7.
71. Mozes E., Sharabi A. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev 2010, 10:22-26.